Wells Fargo & Company MN decreased its position in shares of OvaScience Inc. (NASDAQ:OVAS) by 25.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 127,563 shares of the biotechnology company’s stock after selling 42,604 shares during the period. Wells Fargo & Company MN owned approximately 0.36% of OvaScience worth $239,000 as of its most recent filing with the SEC.
Separately, FMR LLC boosted its stake in shares of OvaScience by 1.3% in the fourth quarter. FMR LLC now owns 5,340,442 shares of the biotechnology company’s stock worth $8,171,000 after buying an additional 66,400 shares during the last quarter. Hedge funds and other institutional investors own 63.66% of the company’s stock.
Shares of OvaScience Inc. (OVAS) opened at 1.55 on Friday. The stock’s market capitalization is $55.28 million. The company’s 50 day moving average is $1.47 and its 200-day moving average is $1.52. OvaScience Inc. has a 52 week low of $1.25 and a 52 week high of $8.98.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.12 million. OvaScience had a negative net margin of 13,227.72% and a negative return on equity of 61.67%. The firm’s revenue was down 56.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.80) earnings per share. On average, equities analysts predict that OvaScience Inc. will post ($1.60) earnings per share for the current year.
WARNING: “Wells Fargo & Company MN Sells 42,604 Shares of OvaScience Inc. (OVAS)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/21/wells-fargo-company-mn-sells-42604-shares-of-ovascience-inc-ovas.html.
A number of analysts recently commented on OVAS shares. Credit Suisse Group restated an “underperform” rating and set a $1.00 price target on shares of OvaScience in a research note on Tuesday, April 18th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of OvaScience in a research note on Friday, May 12th. Zacks Investment Research cut shares of OvaScience from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a research note on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. OvaScience has an average rating of “Hold” and a consensus price target of $6.38.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
